Arcus Biosciences Reports Material Agreement, Equity Sales, Officer Comp Changes
Ticker: RCUS · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1724521
Complexity: simple
Sentiment: mixed
Topics: material-agreement, equity-sales, officer-compensation, corporate-governance
TL;DR
**Arcus Biosciences just made big moves with new agreements, equity sales, and officer pay changes.**
AI Summary
Arcus Biosciences, Inc. filed an 8-K on January 30, 2024, reporting events from January 29, 2024, including entering into a material definitive agreement, unregistered sales of equity securities, and changes in compensatory arrangements for certain officers. This matters to investors because these actions often signal strategic shifts, potential capital raises, or changes in executive compensation, which can impact the company's financial health and future direction.
Why It Matters
This filing indicates significant corporate actions, including potential fundraising and executive compensation adjustments, which can directly influence the company's financial stability and operational strategy.
Risk Assessment
Risk Level: medium — The filing mentions unregistered sales of equity securities, which could dilute existing shareholders if not managed effectively, and changes in officer compensation, which can be a mixed signal.
Analyst Insight
Investors should investigate the specifics of the 'Material Definitive Agreement' and the 'Unregistered Sales of Equity Securities' to understand their potential impact on future share value and company strategy. Details on 'Compensatory Arrangements of Certain Officers' should also be reviewed for alignment with shareholder interests.
Key Players & Entities
- Arcus Biosciences, Inc. (company) — the registrant filing the 8-K
- January 29, 2024 (date) — date of earliest event reported
- January 30, 2024 (date) — date the 8-K was filed
- 001-38419 (other) — Commission File Number
- Delaware (other) — State of Incorporation for Arcus Biosciences, Inc.
FAQ
What was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 29, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
What specific types of information are included in this 8-K filing, according to the 'ITEM INFORMATION' section?
The 'ITEM INFORMATION' section indicates the filing includes details on 'Entry into a Material Definitive Agreement', 'Unregistered Sales of Equity Securities', 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', 'Other Events', and 'Financial Statements and Exhibits'.
What is the Central Index Key (CIK) for Arcus Biosciences, Inc.?
The Central Index Key (CIK) for Arcus Biosciences, Inc. is 0001724521, as listed under 'FILER: COMPANY DATA'.
Where is Arcus Biosciences, Inc.'s principal executive office located?
Arcus Biosciences, Inc.'s principal executive office is located at 3928 Point Eden Way, Hayward, California 94545, as stated in the filing.
What is the Commission File Number for Arcus Biosciences, Inc.?
The Commission File Number for Arcus Biosciences, Inc. is 001-38419, as indicated in the filing.
Filing Stats: 1,183 words · 5 min read · ~4 pages · Grade level 11.4 · Accepted 2024-01-30 08:17:44
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share RCUS The New York Stock Excha
- $21.00 — y's common stock at a purchase price of $21.00 per share (the "2024 Gilead Financing")
- $100,000,000 — ucture, (ii) requires Gilead to pay the $100,000,000 option continuation payment due on the
Filing Documents
- rcus-20240129.htm (8-K) — 35KB
- ex991.htm (EX-99.1) — 34KB
- image_0.jpg (GRAPHIC) — 10KB
- image_1.jpg (GRAPHIC) — 18KB
- 0001724521-24-000034.txt ( ) — 253KB
- rcus-20240129.xsd (EX-101.SCH) — 2KB
- rcus-20240129_def.xml (EX-101.DEF) — 3KB
- rcus-20240129_lab.xml (EX-101.LAB) — 26KB
- rcus-20240129_pre.xml (EX-101.PRE) — 14KB
- rcus-20240129_htm.xml (XML) — 3KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. Third Amended and Restated Common Stock Purchase Agreement On January 29, 2024, Arcus Biosciences, Inc. (the "Company") and Gilead Sciences, Inc. ("Gilead") entered into a Third Amended and Restated Common Stock Purchase Agreement (the "A&R Purchase Agreement"), which amends and restates in its entirety the Second Amended & Restated Common Stock Purchase Agreement dated June 27, 2023 (the "Existing Purchase Agreement"). Pursuant to the A&R Purchase Agreement, Gilead purchased from the Company 15,238,095 shares of the Company's common stock at a purchase price of $21.00 per share (the "2024 Gilead Financing"). All other terms of the Existing Purchase Agreement, including Gilead's option to purchase additional shares from the Company, up to a maximum of 35% of the Company's then-outstanding common stock, from time to time until July 13, 2025, remain unchanged. Amended and Restated Investor Rights Agreement On January 29, 2024, the Company and Gilead entered into an Amended and Restated Investor Rights Agreement (the "A&R Investor Rights Agreement"), which amends and restates in its entirety the Investor Rights Agreement dated May 27, 2020, as amended on October 11, 2022 (as previously amended, the "Existing Investor Rights Agreement"). Pursuant to the A&R Investor Rights Agreement, and in connection with the 2024 Gilead Financing, (i) Gilead has the right to designate up to three individuals to be appointed to the Company's board of directors (the "Board"), (ii) Juan Jaen, Ph.D. and Jennifer Jarrett would resign from the Board , and (iii) the Company agreed to establish a Science Committee and any director appointed by Gilead having an advanced scientific degree shall be a member of such Science Committee. All other terms of the Existing Investor Rights Agreement, remain unchanged. Amendment No. 3 to Option, License and Collaboration Agreement On January 29, 2024, the Company and Gilead also entered into Amen
02 Unregistered Sales of Equity Securities
Item 3.02 Unregistered Sales of Equity Securities. The information set forth in Item 1.01 above related to the Gilead Financing is incorporated by reference here. The shares were sold to Gilead pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and were sold to one entity that is an accredited investor. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 29, 2024 (i) Dr. Jaen and Ms. Jarrett resigned from the Board and (ii) following such resignations, the Board appointed Johanna Mercier to the Board as a Class II director. Dr. Jaen and Ms. Jarrett's resignations are not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company. Ms. Mercier is the Chief Commercial Officer of Gilead and is being appointed pursuant to Gilead's rights under the A&R Investor Rights Agreement and will not receive any compensation for her service as a member of the Board. The Company expects to enter into its standard form of indemnification agreement with Ms. Mercier.
01 Other Events
Item 8.01 Other Events. On January 29, 2024, the Company issued a press release announcing various updates regarding its anti-TIGIT clinical development program. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated January 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCUS BIOSCIENCES, INC. Date: January 30, 2024 By: /s/ Terry Rosen, Ph. D. Terry Rosen, Ph.D. Chief Executive Officer (Principal Executive Officer)